New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
New molecular imaging techniques show promise in improving cancer surgery precision and outcomes.
Memorial Sloan Kettering researchers uncover how pancreatic cancer cells suppress immune triggers by manipulating genetic elements.
A new research center and FDA-backed diversity mandates aim to reshape clinical trial equity and representation across the …
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
A landmark Phase 3 clinical trial led by researchers at Mass General Brigham has demonstrated that inebilizumab, a …
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
With all three Phase 3 trials now enrolling, Akero Therapeutics is racing to bring its promising MASH therapy, …
With a fresh $153 million in funding, Strand Therapeutics is pushing the boundaries of mRNA technology—this time, in …
With a landmark $277 million raise, Element Biosciences is scaling its AVITI™ platform and diving deep into multi-omics—reshaping …
Despite a muted IPO market and cautious M&A activity, biotech in 2024 proved that innovation never sleeps—especially when …
Already a subscriber? Log in